AbbVie Inc (ABBV)vsKiniksa Pharmaceuticals Ltd (KNSA)
ABBV
AbbVie Inc
$257.60
-2.24%
HEALTHCARE · Cap: $447.53B
KNSA
Kiniksa Pharmaceuticals Ltd
$78.20
-3.36%
HEALTHCARE · Cap: $4.81B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 8231% more annual revenue ($62.82B vs $754.04M). KNSA leads profitability with a 9.7% profit margin vs 5.8%. KNSA trades at a lower P/E of 70.3x. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
KNSA
Buy53
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-78.8%
Fair Value
$147.26
Current Price
$257.60
$110.34 premium
Margin of Safety
+76.7%
Fair Value
$192.76
Current Price
$78.20
$114.56 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Generating 3.6B in free cash flow
Revenue surging 55.5% year-over-year
Earnings expanding 145.5% YoY
Conservative balance sheet, low leverage
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
Trading at 9.5x book value
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.42 suggests the stock is reasonably priced for its growth.
Bull Case : KNSA
The strongest argument for KNSA centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 55.5% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 124.8x leaves little room for execution misses.
Bear Case : KNSA
The primary concerns for KNSA are Price/Book, P/E Ratio. A P/E of 70.3x leaves little room for execution misses.
Key Dynamics to Monitor
ABBV profiles as a value stock while KNSA is a hypergrowth play — different risk/reward profiles.
ABBV carries more volatility with a beta of 0.28 — expect wider price swings.
KNSA is growing revenue faster at 55.5% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 53/100) and 12.4% revenue growth. KNSA offers better value entry with a 76.7% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Kiniksa Pharmaceuticals Ltd
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Kiniksa Pharmaceuticals Ltd. (KNSA) is an innovative biopharmaceutical company focused on developing breakthrough therapies to address pressing unmet medical needs, particularly in the realm of autoimmune disorders. Its flagship candidate, KPL-404, is a monoclonal antibody designed to effectively modulate immune responses, positioning Kiniksa at the forefront of promising therapeutic advancements. The company boasts a strong clinical pipeline supported by strategic partnerships that enhance its research and development capabilities. With a dedication to transforming treatment paradigms and a robust growth trajectory, Kiniksa represents an attractive opportunity for institutional investors seeking impactful investments in the evolving healthcare landscape.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?